We use cookies

Our website uses essential cookies and, with your consent, additional cookies to measure performance and improve our services. Cookie Policy.

You can change your choice at any time.

MMedXYNews
HomeVideos
© 2026 MedXY
Contact usAbout usPrivacy PolicyMedXY story
MedXY AI/MedXY News/Pediatrics

Pediatrics

Ask MedXY AI
What is the latest evidence?Key clinical updatesGuideline changes

Latest news

Plasma GFAP and NfL Levels Predict Acute Brain Injury and Poor Outcomes in Pediatric ECMO
Critical CarebiomarkersECMO

Plasma GFAP and NfL Levels Predict Acute Brain Injury and Poor Outcomes in Pediatric ECMO

By MedXY|Mar 2, 2026

This multi-center study demonstrates that serial monitoring of plasma GFAP and NfL biomarkers can detect acute brain injury in pediatric ECMO patients before imaging diagnosis, significantly correlating with long-term survival and functiona

Plasma GFAP and NfL as Real-Time Predictors of Brain Injury and Long-Term Disability in Pediatric ECMO
Critical Carebiomarkersneurocritical care

Plasma GFAP and NfL as Real-Time Predictors of Brain Injury and Long-Term Disability in Pediatric ECMO

By MedXY|Mar 2, 2026

A prospective study demonstrates that rising levels of plasma GFAP and NfL precede neuroimaging-confirmed brain injury in children on ECMO. These biomarkers are also strongly associated with mortality and long-term functional impairment, of

Optimizing Pediatric Outcomes: Evidence-Based Advancements in Respiratory Delivery, Neonatal Support, and Precision Therapeutics
Clinical Updatesclinical trialsneonatal care

Optimizing Pediatric Outcomes: Evidence-Based Advancements in Respiratory Delivery, Neonatal Support, and Precision Therapeutics

By MedXY|Mar 2, 2026

This review synthesizes practice-changing pediatric research, highlighting how device selection in acute wheezing, automated oxygen titration in neonates, and novel siRNA therapies for hypercholesterolemia are redefining clinical standards

Fractional Yellow Fever Vaccination Fails Non-Inferiority in Infants: Why Adult Data Cannot Be Extrapolated to Pediatric Populations
Infectious Diseasesglobal healthPediatrics

Fractional Yellow Fever Vaccination Fails Non-Inferiority in Infants: Why Adult Data Cannot Be Extrapolated to Pediatric Populations

By MedXY|Mar 2, 2026

A randomized, double-blind trial in Kenya and Uganda reveals that a 500 IU fractional dose of yellow fever vaccine is not non-inferior to the standard dose in infants, suggesting that lower dose requirements in adults are not generalizable

Cyclic Exclusive Enteral Nutrition: A New Paradigm for Drug-Free Remission in Pediatric Crohn’s Disease
GastroenterologyCrohn’s disease肠内营养

Cyclic Exclusive Enteral Nutrition: A New Paradigm for Drug-Free Remission in Pediatric Crohn’s Disease

By MedXY|Mar 2, 2026

The CD-HOPE trial reveals that cyclic exclusive enteral nutrition (C-EEN) is superior to daily partial enteral nutrition (PEN) for maintaining drug-free remission in children with Crohn’s disease, providing a critical alternative to long-te

Twice-Yearly Inclisiran Successfully Lowers LDL-C in Adolescents with Heterozygous Familial Hypercholesterolaemia: Insights from ORION-16
CardiologyCardiologyInclisiran

Twice-Yearly Inclisiran Successfully Lowers LDL-C in Adolescents with Heterozygous Familial Hypercholesterolaemia: Insights from ORION-16

By MedXY|Feb 24, 2026

The ORION-16 trial demonstrates that inclisiran, a twice-yearly siRNA therapy, significantly and safely reduces LDL cholesterol in adolescents with HeFH, offering a potent new tool for early cardiovascular risk management in high-risk pedia

CIFFREO Trial Results: Fordadistrogene Movaparvovec Fails Primary Efficacy Endpoint in Duchenne Muscular Dystrophy
NeurologyCIFFREO Trialgene therapy

CIFFREO Trial Results: Fordadistrogene Movaparvovec Fails Primary Efficacy Endpoint in Duchenne Muscular Dystrophy

By MedXY|Feb 24, 2026

The Phase 3 CIFFREO trial for the gene therapy fordadistrogene movaparvovec failed to meet its primary efficacy endpoint in boys with Duchenne muscular dystrophy, showing no significant functional improvement over placebo and leading to the

Giving Kids a Voice: How Patient-Reported Outcome Measures are Transforming Pediatric Specialty Care
newsclinical trialhealth communication

Giving Kids a Voice: How Patient-Reported Outcome Measures are Transforming Pediatric Specialty Care

By MedXY|Feb 25, 2026

Explore how standardized health questionnaires empower children and parents to share their priorities in medical settings, leading to more personalized and effective treatment plans.

AAV9 Gene Therapy Shows Clinical Promise in Stabilizing Type II GM1 Gangliosidosis
Neurologygene therapyneurology

AAV9 Gene Therapy Shows Clinical Promise in Stabilizing Type II GM1 Gangliosidosis

By MedXY|Feb 23, 2026

A Phase 1-2 trial of AAV9-GLB1 gene therapy in children with Type II GM1 gangliosidosis demonstrates significant biochemical improvements and stabilization of neurodevelopmental decline, marking a pivotal step toward treating this fatal lys

Kangaroo Care Attenuates Pain and Systemic Inflammatory Markers During Retinopathy of Prematurity Screening
news未熟児網膜症

Kangaroo Care Attenuates Pain and Systemic Inflammatory Markers During Retinopathy of Prematurity Screening

By MedXY|Feb 25, 2026

A randomized clinical trial demonstrates that Kangaroo care significantly reduces pain-related stress and systemic inflammatory responses in preterm infants undergoing retinopathy screening, suggesting a simple, non-pharmacological interven

Ultrasound Viscoelastic Imaging: A New Noninvasive Frontier in Pediatric Henoch-Schönlein Purpura Nephritis Diagnosis
newsultrasound

Ultrasound Viscoelastic Imaging: A New Noninvasive Frontier in Pediatric Henoch-Schönlein Purpura Nephritis Diagnosis

By MedXY|Feb 23, 2026

This study highlights ultrasound viscoelastic imaging as a high-performance, noninvasive tool for diagnosing Henoch-Schönlein purpura nephritis (HSPN) in children, achieving a combined AUC of 0.95 and providing critical insights into renal

Early Selective Ibuprofen for Patent Ductus Arteriosus Fails to Improve Outcomes in Extremely Preterm Infants: Insights from the Baby-OSCAR Trial
Cardiologybronchopulmonary dysplasiaibuprofen

Early Selective Ibuprofen for Patent Ductus Arteriosus Fails to Improve Outcomes in Extremely Preterm Infants: Insights from the Baby-OSCAR Trial

By MedXY|Feb 20, 2026

The Baby-OSCAR trial demonstrates that early selective treatment of large patent ductus arteriosus with ibuprofen in extremely preterm infants does not significantly reduce death or bronchopulmonary dysplasia, nor does it improve neurodevel

Prophylactic Acetaminophen Fails to Improve Intact Survival in Preterm Infants: Lessons from the TREOCAPA Trial
CardiologyacetaminophenNeonatology

Prophylactic Acetaminophen Fails to Improve Intact Survival in Preterm Infants: Lessons from the TREOCAPA Trial

By MedXY|Feb 20, 2026

The TREOCAPA randomized clinical trial demonstrates that while prophylactic intravenous acetaminophen effectively promotes patent ductus arteriosus closure in extremely preterm infants, it does not significantly increase survival without se

Universal School-Based Mindfulness Fails to Outperform Standard Care for Adolescent Mental Health: Insights from the MYRIAD Trial
newsAdolescent Depressionmachine learning

Universal School-Based Mindfulness Fails to Outperform Standard Care for Adolescent Mental Health: Insights from the MYRIAD Trial

By MedXY|Feb 19, 2026

A large-scale analysis of the MYRIAD trial indicates that universal school-based mindfulness training does not superiorly reduce depression risk in adolescents. While machine learning identified certain potential responders, the clinical be

Beyond the Daily Pill: The Dawn of Long-Acting HIV Treatment for Adolescents
newsadolescent healthHIV/AIDS

Beyond the Daily Pill: The Dawn of Long-Acting HIV Treatment for Adolescents

By MedXY|Feb 19, 2026

The IMPAACT 2017/MOCHA study reveals that long-acting injectable cabotegravir and rilpivirine administered every eight weeks is safe and highly effective for adolescents with HIV, potentially transforming the landscape of pediatric HIV care

Beyond End-of-Life: The Rising Global Burden of Chronic Suffering in 10.6 Million Children
newsChronic Disease Managementglobal health

Beyond End-of-Life: The Rising Global Burden of Chronic Suffering in 10.6 Million Children

By MedXY|Feb 17, 2026

A landmark longitudinal study reveals that 10.6 million children experience serious health-related suffering annually, with a critical shift toward survivors requiring long-term palliative support rather than end-of-life care, predominantly

Why Environmental Interventions in Childcare May Not Be Enough: Insights from the NAPSACC UK Trial
newsPediatricspublic health

Why Environmental Interventions in Childcare May Not Be Enough: Insights from the NAPSACC UK Trial

By MedXY|Feb 17, 2026

The NAPSACC UK cluster RCT found that a one-year environmental intervention in early childhood education settings did not significantly improve total energy consumption or physical activity, highlighting the need for broader policy-level ch

Surgical Fixation Offers No Clinical Benefit and Zero Cost-Effectiveness for Pediatric Medial Epicondyle Fractures: Results from the SCIENCE Trial
newshealth economicsrandomized controlled trial

Surgical Fixation Offers No Clinical Benefit and Zero Cost-Effectiveness for Pediatric Medial Epicondyle Fractures: Results from the SCIENCE Trial

By MedXY|Feb 16, 2026

The SCIENCE multicentre randomized trial demonstrates that surgical fixation for displaced medial epicondyle fractures in children provides no functional advantage over non-surgical care, carries higher complication risks, and is not a cost

Dolutegravir and Metabolic Health in Children: Five-Year Insights from the ODYSSEY Trial
newsdolutegravirmetabolic health

Dolutegravir and Metabolic Health in Children: Five-Year Insights from the ODYSSEY Trial

By MedXY|Feb 14, 2026

Ancillary analysis of the ODYSSEY trial demonstrates that dolutegravir-based ART is not associated with excessive weight gain or adiposity in children and adolescents compared to standard care, while offering a superior metabolic profile ov

Paracetamol vs. Ibuprofen in Infancy: The PIPPA Tamariki Trial Finds No Differential Risk for Eczema or Bronchiolitis
Allergy & ImmunologybronchiolitisEczema

Paracetamol vs. Ibuprofen in Infancy: The PIPPA Tamariki Trial Finds No Differential Risk for Eczema or Bronchiolitis

By MedXY|Feb 14, 2026

The PIPPA Tamariki randomized controlled trial demonstrates that using paracetamol versus ibuprofen as needed in the first year of life does not significantly alter the risk of developing eczema or bronchiolitis by age one, challenging long

Prev
10 / 25
1…89101112…25
Next
Ask MedXY AI

Most popular

Intimate Health
Five Benefits for Women Continuing Sexual Activity After Menopause
Intimate Health
Why Some Women Have a Strong Sex Drive—And Why Men Shouldn't Worry About It
Nursing & care
How often should a couple have sex?
Intimate Health
Classic Intimacy Recommendations: How to Help Women Reach Orgasm and Enjoy Mutual Pleasure
Intimate Health
What Makes a Woman "Physiologically Addicted" Is Never Money, But These Two Relationship Qualities

Browse by specialty

Open language-specific specialty feeds and department pages.

news6629 articlesCardiology1375 articlesClinical Updates1288 articlesOncology1139 articlesDiabetes & Endocrinology842 articlesNeurology820 articlesPublic Health595 articlesGastroenterology572 articles
Hematology-Oncology
487 articles
Pediatrics484 articles
Internal Medicine444 articles